Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Baxter Completes Lyophilization Expansion

  • Baxter BioPharma Solutions reports that it has finished the lyophilization capacity expansion at their cytotoxic contract manufacturing facility in Halle, Germany. The company now has four dedicated lyophilizers and over 1,100 sq. ft.

    To freeze-dry clients’ cancer therapy drugs, two large-scale lyophilization units were added. The expansion also includes  technologies to handle organic solvents, including a fully automated loading cart and in-process quality analysis technology.  The cart navigates in the building with sensors, transporting the cytotoxic vials from filling without human attendance, and auto-loads the freeze driers.

    “Our experience in barrier isolators enabled us to realize this cutting edge technology while considering specific customer requests,” says Thomas Julien, director of manufacturing. “By using the latest technology, we eliminate human exposure to the cytotoxics, and reduce contamination-risk of the products.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »